Sign up
Pharma Capital

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program.

He says they've now successfully optimised the conditions for extracting cannabinoids from one of their cannabis strains … ''we've also quantified how much of each of those cannabinoids are present within that extract and it falls well within the range of what the provider of that cannabis strain specified to us'', he adds.

''We're very confident now moving forward, developing a standard operating procedure to extract it from the remaining four strains''.

 

View full PREV profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.